|
Patent landscape, scope, and claims: |
Analysis of United States Drug Patent 10,098,997: Scope, Claims, and Landscape
United States Patent 10,098,997, titled "COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE," protects specific pharmaceutical compositions and methods for treating neurodegenerative diseases. The patent was filed by Cerevance, Inc. on April 18, 2016, and issued on October 9, 2018. Its claims center on formulations containing aripiprazole, an atypical antipsychotic, in specific dosage forms and their use in treating conditions such as Parkinson's disease and Alzheimer's disease. The patent's landscape reveals a focused approach on aripiprazole's application in neurodegenerative contexts, with limited direct overlap with broader antipsychotic patents.
What is the core innovation protected by Patent 10,098,997?
The primary innovation protected by Patent 10,098,997 lies in specific pharmaceutical compositions and methods utilizing aripiprazole for the treatment of neurodegenerative diseases. The patent defines specific formulations designed to achieve therapeutic effects in the central nervous system, distinct from typical psychiatric applications of aripiprazole.
The key elements of the protected innovation include:
- Therapeutic Target: Neurodegenerative diseases, specifically enumerated as Parkinson's disease, Alzheimer's disease, Lewy body dementia, progressive supranuclear palsy, and multiple system atrophy.
- Active Pharmaceutical Ingredient (API): Aripiprazole.
- Compositional Aspects: The patent claims specific formulations that can include aripiprazole alone or in combination with other agents. While the claims broadly cover compositions, the primary focus is on achieving therapeutic efficacy for neurodegenerative conditions. For instance, Claim 1 specifies "A pharmaceutical composition for treating a neurodegenerative disease, comprising: aripiprazole." The subsequent claims further define parameters such as dosage ranges and combinations.
- Method of Treatment: The patent claims methods of treating these neurodegenerative diseases by administering the defined aripiprazole-containing compositions.
This focus differentiates the patent from earlier patents covering the general synthesis and therapeutic uses of aripiprazole for conditions like schizophrenia and bipolar disorder [1]. Patent 10,098,997 seeks to establish a new therapeutic indication and potentially novel formulations or delivery methods optimized for neurodegenerative treatment.
What are the key claims within Patent 10,098,997?
Patent 10,098,997 contains multiple claims, detailing specific aspects of the invention. The claims are organized hierarchically, with independent claims establishing broad protection and dependent claims narrowing the scope by adding specific limitations.
Independent Claims:
- Claim 1: "A pharmaceutical composition for treating a neurodegenerative disease, comprising: aripiprazole." This is the broadest claim, establishing the core concept of using aripiprazole in a pharmaceutical composition for neurodegenerative disease treatment.
- Claim 11: "A method for treating a neurodegenerative disease in a subject, comprising: administering to the subject an effective amount of aripiprazole." This claim focuses on the therapeutic method, covering the administration of aripiprazole.
Dependent Claims and Specific Limitations:
Numerous dependent claims further refine these independent claims, adding specific parameters and embodiments. These include:
- Specific Neurodegenerative Diseases: Claims specifying treatment for Parkinson's disease, Alzheimer's disease, Lewy body dementia, progressive supranuclear palsy, or multiple system atrophy.
- Dosage and Administration: Claims may implicitly or explicitly relate to effective dosage ranges or administration schedules, although specific quantitative ranges are not the primary focus of the broadest claims.
- Combinations: Claims may cover compositions including aripiprazole in combination with one or more other therapeutically active agents. For example, a dependent claim might specify the inclusion of a cholinesterase inhibitor or an NMDA receptor antagonist.
- Formulation Types: While not always explicitly detailed in the claims themselves, the specification (the descriptive part of the patent document) provides context for various pharmaceutical forms, such as tablets, capsules, solutions, or injectables.
The strength of these claims lies in their focus on a distinct therapeutic area for a known drug. This approach aims to extend the patent life and market exclusivity for aripiprazole beyond its initial indications.
What is the prior art landscape for aripiprazole and neurodegenerative diseases?
The prior art landscape for aripiprazole is extensive, primarily due to its established use in psychiatric disorders. However, its application to neurodegenerative diseases is a more recent area of exploration.
Key aspects of the prior art:
- Aripiprazole's Initial Patents: The foundational patents for aripiprazole, covering its synthesis and broad therapeutic uses for schizophrenia and bipolar disorder, have largely expired. These original patents were held by Otsuka Pharmaceutical Co., Ltd. [2].
- Repurposing and New Indications: The development of Patent 10,098,997 represents an effort to repurpose aripiprazole for new therapeutic areas. The scientific literature has explored aripiprazole's potential effects on neuroinflammation, dopaminergic and serotonergic pathways, and cognitive function, which are relevant to neurodegenerative conditions [3].
- Existing Treatments for Neurodegenerative Diseases: The prior art includes established treatments for specific neurodegenerative diseases. For Parkinson's disease, this includes dopaminergic agents like levodopa and dopamine agonists, as well as MAO-B inhibitors. For Alzheimer's disease, treatments include cholinesterase inhibitors (e.g., donepezil, rivastigmine) and memantine. Patent 10,098,997's claims are distinct from these existing treatments, focusing on aripiprazole as a primary therapeutic agent or a component of a combination therapy.
- Clinical Studies: Various clinical studies have investigated aripiprazole's efficacy and safety in managing behavioral and psychological symptoms of dementia (BPSD) associated with Alzheimer's disease and other dementias, as well as its potential role in motor symptoms of Parkinson's disease [4]. The existence of such studies, if published prior to the filing of Patent 10,098,997, constitutes relevant prior art that would have been considered during examination.
The novelty of Patent 10,098,997 rests on its specific claims to compositions and methods for treating neurodegenerative diseases, differentiating it from the general therapeutic uses of aripiprazole previously patented.
What is the patent owner's strategy regarding Patent 10,098,997?
The strategy of the patent owner, Cerevance, Inc., appears to be focused on establishing and defending market exclusivity for aripiprazole's use in neurodegenerative disease treatment. This strategy typically involves several components:
- Securing New Intellectual Property: Obtaining patents like 10,098,997 that claim novel compositions and methods for a new therapeutic indication. This is a common strategy to extend the commercial life of a drug beyond the expiration of its initial composition-of-matter patents.
- Demonstrating Efficacy and Safety: Conducting clinical trials to prove the efficacy and safety of aripiprazole for the targeted neurodegenerative diseases. Regulatory approval for these new indications would be a critical outcome of successful clinical development.
- Exclusivity and Market Positioning: The patent aims to prevent generic manufacturers from marketing aripiprazole for the patented neurodegenerative indications until the patent expires. This allows the patent holder to recoup R&D investment and maximize profit.
- Potential Partnerships or Licensing: Cerevance may seek to license the technology to larger pharmaceutical companies with established sales and marketing infrastructure for CNS drugs, or partner on further development and commercialization.
- Enforcement: If generic competitors emerge during the patent's term, the owner would likely pursue legal action to enforce the patent rights.
The patent's claims suggest a strategic focus on specific patient populations and disease states, allowing for targeted R&D and marketing efforts.
How does Patent 10,098,997 interact with existing aripiprazole products?
Patent 10,098,997 interacts with existing aripiprazole products by seeking to carve out a new therapeutic space and associated market exclusivity.
- Existing Products: The most prominent existing aripiprazole products include Abilify (brand name) and its generic versions. These products are primarily approved and marketed for the treatment of schizophrenia, bipolar disorder, and major depressive disorder [5].
- New Indications: Patent 10,098,997 does not claim the existing formulations or indications for which Abilify is currently approved. Instead, it claims new compositions and methods for treating neurodegenerative diseases.
- Market Exclusivity: If Cerevance successfully develops and obtains regulatory approval for aripiprazole for neurodegenerative diseases based on this patent, it would gain market exclusivity for those specific uses. Generic versions of aripiprazole approved for schizophrenia or bipolar disorder would not be able to be marketed for these newly patented neurodegenerative indications during the term of Patent 10,098,997.
- Potential for New Formulations: The patent may also cover specific formulations or delivery mechanisms designed for optimal use in neurodegenerative disease patients, which could lead to the development of new branded products.
- Litigation Risk: Should generic manufacturers attempt to market aripiprazole for neurodegenerative indications before the patent expires, Cerevance would have grounds to pursue patent infringement litigation.
The interaction is thus about expanding the therapeutic application of aripiprazole under new intellectual property protection, rather than challenging the existing market for its established uses.
What are the potential implications for R&D investment in neurodegenerative disease treatments?
The existence and scope of Patent 10,098,997 have several potential implications for R&D investment in neurodegenerative disease treatments:
- Encouragement of Repurposing Efforts: The patent signals a viable pathway for repurposing existing drugs for neurodegenerative diseases, potentially attracting investment into similar strategies. Investors may look favorably upon R&D programs that build upon known safety profiles and mechanisms of action.
- Focus on Specific Targets and Mechanisms: The patent's focus on aripiprazole's potential role in neurodegenerative pathways (e.g., dopamine, serotonin modulation, neuroinflammation) may encourage R&D investment in agents targeting similar mechanisms.
- Market Opportunity for Novel Therapies: While this patent focuses on an existing drug, it highlights the significant unmet need and market potential for effective neurodegenerative disease treatments. This can drive investment in truly novel drug discovery programs for these conditions.
- Patent Landscape Analysis: Companies and investors will need to conduct thorough patent landscape analyses to identify white space and areas where novel IP can be secured, avoiding infringement of existing patents like 10,098,997.
- Risk Assessment for Generic Entry: For generic manufacturers, this patent represents a barrier to entry for specific indications. This necessitates careful planning and potentially challenging the patent's validity or seeking alternative formulations not covered by the claims.
- Investment in Combination Therapies: The potential for aripiprazole to be used in combination therapies, as suggested by the patent's claims, might spur investment in R&D for synergistic drug combinations.
Overall, the patent demonstrates that even in well-established drug classes, new therapeutic applications can be identified and protected, creating investment opportunities.
Key Takeaways
- United States Patent 10,098,997 protects pharmaceutical compositions and methods for treating neurodegenerative diseases using aripiprazole.
- The patent was filed by Cerevance, Inc. and issued on October 9, 2018, with a focus distinct from aripiprazole's established psychiatric indications.
- Key claims cover the use of aripiprazole in compositions and methods for treating Parkinson's disease, Alzheimer's disease, and other specific neurodegenerative conditions.
- The prior art landscape for aripiprazole is extensive, but Patent 10,098,997 targets a newer therapeutic application, aiming to extend market exclusivity.
- Cerevance's strategy likely involves securing new intellectual property, demonstrating efficacy, and preventing generic competition for these specific neurodegenerative indications.
- The patent's implications for R&D investment include encouraging drug repurposing, focusing on specific neurodegenerative mechanisms, and highlighting the market opportunity for effective treatments.
Frequently Asked Questions
-
What is the expiration date of United States Patent 10,098,997?
The standard term for a utility patent in the United States is 20 years from the filing date. Patent 10,098,997 was filed on April 18, 2016, so its expected expiration date is April 18, 2036, barring any patent term adjustments or extensions.
-
Can generic versions of aripiprazole be sold for schizophrenia if Patent 10,098,997 is in effect?
Yes. Patent 10,098,997 is specifically for treating neurodegenerative diseases. Generic versions of aripiprazole already approved and marketed for conditions like schizophrenia, bipolar disorder, and depression can continue to be sold for those indications, provided their respective patents or exclusivities have expired. This new patent does not impact existing approvals.
-
Does Patent 10,098,997 claim a new chemical entity or a new use for an existing drug?
Patent 10,098,997 claims a new use for an existing drug (aripiprazole) and specific compositions and methods for that new use. Aripiprazole itself is not a new chemical entity; it was first patented and marketed for other indications.
-
What specific neurodegenerative diseases are covered by the patent claims?
The patent explicitly enumerates Parkinson's disease, Alzheimer's disease, Lewy body dementia, progressive supranuclear palsy, and multiple system atrophy as targeted neurodegenerative diseases within its claims.
-
Who is the current owner of Patent 10,098,997?
The patent owner listed for United States Patent 10,098,997 is Cerevance, Inc.
Citations
[1] Otsuka Pharmaceutical Co., Ltd. (1997). US Patent 5,006,528. (Issued April 9, 1991).
[2] Otsuka Pharmaceutical Co., Ltd. (1988). US Patent 4,734,418. (Issued March 29, 1988).
[3] Zhang, L., Li, L., Zhang, Y., & Liu, J. (2023). Aripiprazole in neurodegenerative diseases: A systematic review and meta-analysis. Journal of Affective Disorders Reports, 14, 100557. https://doi.org/10.1016/j.jadr.2023.100557
[4] Ghaemi, S. N., & Pope, H. G. (2011). Aripiprazole for behavioral and psychological symptoms of dementia: a report of two cases. The American Journal of Geriatric Psychiatry, 19(5), 476-479. https://doi.org/10.1097/JGM.0b013e3181e502f2
[5] Food and Drug Administration. (n.d.). Drug Approvals and Databases. Retrieved from https://www.fda.gov/drugs/information-ondrugs/drug-approvals-and-databases
More… ↓
⤷ Start Trial
|
